Exelixis, Inc. is restructuring as part of its continued strategy to focus resources on the development of its key late-stage compounds, XL184, XL147 and XL765. The restructuring also includes cutting its workforce by approximately 40%, or 270 employees. Although Exelixis will continue its efforts to advance other new compounds into development, the number will be reduced for the foreseeable future. The company has retained the ability to meet all of its existing obligations to partners and expe...